Stent Market: as Abbott's Esprit BTK resorbable scaffold secures both European CE Mark and a dedicated CMS New Technology Add-on Payment within a matter of weeks, and Boston Scientific's coronary drug-coated balloon receives parallel Medicare reimbursement, below-the-knee peripheral disease is emerging as the stent category's newest reimbursement-backed growth frontier, expanding the market well beyond its historical coronary core.

The global stent market size was USD 10.62 Billion in 2025 and is expected to register a revenue CAGR of 6.2% during the forecast period.Market revenue growth is driven by factors such as the increasing global burden of cardiovascular and peripheral artery disease, drug-eluting stent restenosis superiority data, and bioresorbable scaffold technology maturation expanding into new anatomical indications.The first driving factor is the increasing global burden of cardiovascular disease, with the World Health Organization reporting that cardiovascular diseases account for approximately 17.9 million deaths annually worldwide.The second driving factor is drug-eluting stent restenosis superiority data, continuing to reinforce DES as the dominant coronary stent technology relative to bare-metal alternatives.The third driving factor is bioresorbable scaffold technology maturation, extending beyond the technology's original coronary application into peripheral artery disease, particularly the below-the-knee indication frontier that has historically lacked dedicated device options.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single reimbursement policy decision, once secured for a genuinely novel device category, widens the addressable procedure volume for that category faster than clinical adoption curves alone would predict, converting regulatory approval into an economically viable therapy almost immediately rather than over a multi-year adoption ramp.Once a stent or scaffold technology addressing a previously underserved anatomical indication secures both regulatory approval and dedicated reimbursement, hospitals gain a clear economic case for adopting the new procedure category without needing to absorb the cost themselves during an extended technology evaluation period, so procedure volume can scale close to the pace of physician training rather than being held back by reimbursement uncertainty.As a result, demand and revenue share are concentrating around manufacturers whose novel technologies achieve both regulatory approval and reimbursement coverage in close succession, that hold the deepest combined clinical evidence and payer engagement capability, and the forecast tilts toward these reimbursement-secured innovators rather than manufacturers whose novel technologies lack a clear payment pathway.For instance, Abbott's Esprit BTK Everolimus Eluting Resorbable Scaffold System received CE Mark in Europe in August 2025 and a dedicated CMS New Technology Add-on Payment of up to USD 6,922.50 effective October 1, 2025, securing both international regulatory expansion and US reimbursement within approximately five weeks of each other for the first dedicated device treating below-the-knee chronic limb-threatening ischemia.These are some of the key factors driving revenue growth of the market.

Because coronary and peripheral stents carry residual risk of in-stent restenosis and, less commonly, late stent thrombosis, this creates durability uncertainty that continues to drive innovation toward bioresorbable and next-generation drug-eluting technologies rather than settling on current-generation permanent metallic platforms.

Pricing pressure from emerging market domestic manufacturers is a second constraint, as regional stent manufacturers in China, India, and other developing markets offer conventional drug-eluting and bare-metal stents at substantially lower price points than established multinational manufacturers.

Physician training and procedural learning curve requirements are a third constraint, particularly for genuinely novel technologies like below-the-knee bioresorbable scaffolds, where analysts have noted the need for centre training could result in a gradual rather than immediate commercial launch trajectory.

These factors substantially limit stent market growth over the forecast period.

The clearest driver of demand is the extension of bioresorbable scaffold technology into an anatomical indication, below-the-knee peripheral artery disease, that previously had no dedicated stent or drug-eluting device option at all. A novel device technology only achieves rapid commercial adoption if both regulatory approval and reimbursement coverage arrive in close succession, and Abbott's Esprit BTK System achieved exactly that sequencing, receiving CE Mark in Europe on August 25, 2025, followed by a CMS New Technology Add-on Payment of up to USD 6,922.50 effective October 1, 2025. Three-year outcomes from the LIFE-BTK randomised trial, presented at TCT 2025, continued to build the clinical evidence base supporting the resorbable scaffold's reduced rate of vessel re-narrowing compared to conventional balloon angioplasty in chronic limb-threatening ischemia patients. Industry analysts estimated the below-the-knee peripheral artery disease market opportunity at approximately USD 400 Million to USD 500 Million with a 9% compound annual growth rate, with Abbott holding an estimated 29% share of the existing US below-the-knee market entering this new device category. The effect on the market is that bioresorbable scaffold technology, after a period of limited commercial success in its original coronary application, has found a genuinely underserved anatomical indication where the technology's core value proposition, complete resorption after supporting vessel healing, addresses an unmet clinical need more directly than in coronary disease. These are some of the key factors driving revenue growth of the market.

The second driver is the extension of dedicated reimbursement pathways beyond the stent device itself into adjunctive coronary technologies specifically addressing the restenosis complications that stents themselves can cause. A drug-coated balloon technology only captures meaningful procedure volume for treating in-stent restenosis if hospitals have a clear reimbursement pathway that offsets the device's incremental cost relative to repeat percutaneous coronary intervention or cardiac surgery, and Boston Scientific's Agent Drug-Coated Balloon secured a CMS New Technology Add-on Payment effective October 1, 2025, providing exactly that additional payment. The Agent DCB targets scar tissue with a therapeutic dose of paclitaxel specifically to reduce the risk of in-stent restenosis, addressing a complication category that grows in absolute volume as the installed base of previously implanted coronary stents continues to expand globally. CMS uses New Technology Add-on Payments specifically to provide additional reimbursement when newer technologies are associated with significant clinical benefit and costs that could otherwise be high enough to limit hospital implementation, reflecting a policy tool increasingly applied across the coronary and peripheral stent-adjacent device category. The effect on the market is that manufacturers addressing complications and follow-on procedures within the existing stent-implanted patient population are capturing dedicated reimbursement pathways in parallel with novel primary device technologies like the Esprit BTK scaffold. These are some of the key factors driving revenue growth of the market.

“Abbott's Esprit BTK System secured CE Mark in Europe and a CMS New Technology Add-on Payment of up to USD 6,922.50 within approximately five weeks of each other, converting the first dedicated below-the-knee device into an immediately reimbursable therapy rather than one requiring years of adoption before payer support caught up.”

However, the stent market faces severe adoption constraints from in-stent restenosis and late stent thrombosis complication risk, pricing pressure from emerging market domestic manufacturers, and physician training requirements for genuinely novel technologies.

Because coronary and peripheral stents carry residual risk of in-stent restenosis and, less commonly, late stent thrombosis, this creates durability uncertainty that continues to drive innovation toward bioresorbable and next-generation drug-eluting technologies, even as growing complication volume itself sustains demand for adjunctive technologies like drug-coated balloons.

Pricing pressure from emerging market domestic manufacturers compounds this, as regional stent manufacturers in China, India, and other developing markets offer conventional drug-eluting and bare-metal stents at substantially lower price points than established multinational manufacturers, moderating average selling price growth in cost-sensitive developing markets.

Physician training and procedural learning curve requirements are the third constraint, particularly for genuinely novel technologies like the below-the-knee bioresorbable scaffold, where industry analysts specifically noted that the need for dedicated centre training could result in a gradual rather than immediate commercial launch trajectory despite strong underlying demand.

These factors substantially limit stent market growth over the forecast period.

Based on product type, the global stent market is segmented into coronary, peripheral vascular, carotid, and renal/specialty stents. Coronary stents hold the largest revenue share, reflecting the established, high-volume nature of percutaneous coronary intervention procedures performed globally across hospital and ambulatory cardiac catheterisation settings. Peripheral vascular stents are expected to register the fastest revenue growth rate over the forecast period, driven by below-the-knee bioresorbable scaffold expansion at manufacturers including Abbott addressing a previously underserved anatomical indication.

Based on technology, the global stent market is segmented into drug-eluting stents, bare-metal stents, and bioresorbable vascular scaffolds. Drug-eluting stents hold the largest revenue share, reflecting sustained restenosis superiority data reinforcing DES as the dominant coronary stent technology relative to bare-metal alternatives. Bioresorbable vascular scaffolds are expected to register the fastest revenue growth rate, driven by expansion into below-the-knee peripheral artery disease at manufacturers including Abbott, a genuinely new anatomical application for the technology.

Based on regional analysis, the stent market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the headquarters of Boston Scientific, Abbott, and Medtronic's US operations, and because CMS reimbursement policy, including the recent Esprit BTK and Agent DCB New Technology Add-on Payments, directly shapes national procedure volume and technology adoption pace. Medtronic, Boston Scientific, and Abbott together represent a combined market share exceeding 75% globally, with the concentration of these manufacturers' headquarters and commercial infrastructure in the United States reinforcing the country's position as the largest single national stent market. The concentration of leading stent manufacturers in the United States also means new device categories and reimbursement pathways are typically established domestically before being extended to other regions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Italy represent the four largest national markets, with the mandatory EUDAMED data submission deadline of May 28, 2026 shaping manufacturer regulatory compliance timelines across the region. European stent procurement continues to expand alongside established national health service reimbursement frameworks, but complex cross-border trade barriers and tariff considerations create more measured commercial rollout pacing relative to the United States. The result is steady rather than rapid growth, shaped more by regulatory compliance and procurement cycle timing than by underlying cardiovascular disease burden.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period, driven by China, Japan, and India's expanding interventional cardiology infrastructure and rising cardiovascular disease prevalence. China's rapidly expanding domestic stent manufacturing base and hospital network, and Japan's established interventional cardiology training programmes, are the region's two largest growth contributors. This leaves more room for growth than in the more mature North American and European stent markets, where manufacturer-institution relationships are already largely established.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets, with interventional cardiology programme access concentrated at academic medical centres in São Paulo and Mexico City. Iran-US sanctions continue to disrupt freight and import costs for the specialised cobalt-chromium, platinum-chromium, and bioresorbable polymer materials that Latin American stent distributors depend on, with cargo rerouting around the Strait of Hormuz corridor raising landed component costs and slowing stent distribution beyond the region's main academic centres through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC commercial markets, with the Saudi Vision 2030 healthcare investment programme driving new interventional cardiology infrastructure development. The UAE is the most established market on the continent for advanced stent technology adoption, while the Gulf states more broadly are still building specialist interventional cardiology infrastructure largely from scratch.